person · Reporting owner
Kovacs Shane William Charles
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | CH. OPERATING & FINANCIAL OFF. | January 13, 2026 | January 15, 2026 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Chief Financial Officer | May 09, 2017 | May 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date January 13, 2026 · Filed January 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,727 |
Ending reported balance
After 2026-01-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-13 · Sale · Disposed 3,822 · Balance 239,727 F1: The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Row 2 · 2026-01-15 · Sale · Disposed 100,000 · Balance 139,727 F2: The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2: The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
PTC THERAPEUTICS, INC.
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,850 |
Reported balance
After 2017-05-09 transaction · row 1
1 source rowRow 1 · 2017-05-09 · Exercise / conversion · Acquired 10,000 · Balance 37,850 |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2023-05-21 | Direct | 45,625 |
Reported balance
After 2017-05-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-09 · Exercise / conversion · Disposed 10,000 · Balance 45,625 F1: This option award was granted on May 22, 2013, with 25% of the shares underlying the option vested on May 22, 2014, and an additional 2.083% of the original number of shares underlying the option vesting on a monthly basis thereafter, beginning on June 30, 2014. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.05 · Expires 2024-01-27 | Direct | 46,384 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 46,384 F2: This option award was granted on January 28, 2014, with 25% of the shares underlying the option vested on January 1, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.00 · Expires 2025-01-01 | Direct | 85,600 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 85,600 F3: This option award was granted on January 2, 2015, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.86 · Expires 2026-01-03 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 80,000 F4: This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.23 · Expires 2027-01-02 | Direct | 52,500 |
Reported balance
Holding disclosure · report date 2017-05-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 52,500 F5: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award was granted on May 22, 2013, with 25% of the shares underlying the option vested on May 22, 2014, and an additional 2.083% of the original number of shares underlying the option vesting on a monthly basis thereafter, beginning on June 30, 2014.
F2: This option award was granted on January 28, 2014, with 25% of the shares underlying the option vested on January 1, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015.
F3: This option award was granted on January 2, 2015, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
F4: This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
F5: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2026 Filed Jan 15, 2026 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 100,000 | $28.73 | $2,873,000.00 |
DisclosureSEC source: 0001579397-26-000002 · form4-01152026_090101.xml · nonDerivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,727 F2 · price: The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,822 | $28.01 | $107,054.22 |
DisclosureSEC source: 0001579397-26-000002 · form4-01152026_090101.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,727 F1 · price: The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GiftCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001579397-25-000007 · form4-12092025_091203.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,549 F1 · kind: The reporting person transferred 75,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GiftCommon Stock | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001579397-25-000005 · form4-12012025_091201.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,549 F1 · kind: The reporting person transferred 225,000 shares to the Kovacs 2025 Family Trust as a bona fide gift for no consideration. The reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:16 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001415889-25-006151 · form4-03032025_090344.xml · derivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 11, 2024 Filed Dec 11, 2024 19:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 406 | $9.39 | $3,812.34 |
DisclosureSEC source: 0001415889-24-029025 · form4-12122024_121223.xml · nonDerivative · entry 4 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,549 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 11, 2024 19:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 17,950 | $8.66 | $155,447.00 |
DisclosureSEC source: 0001415889-24-029025 · form4-12122024_121223.xml · nonDerivative · entry 3 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,955 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 19:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 16,803 | $9.37 | $157,444.11 |
DisclosureSEC source: 0001415889-24-029025 · form4-12122024_121223.xml · nonDerivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,905 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.87 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 19:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 68,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029025 · form4-12122024_121223.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,708 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 105,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 06:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-24-027022 · form4-11182024_061102.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 06:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 25,000 | $7.02 | $175,500.00 |
DisclosureSEC source: 0001415889-24-027022 · form4-11182024_061102.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 471 shares acquired under the issuer's Employee Stock Purchase Plan on June 28, 2024. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 17:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 304,500 | $0.00 Strike: $15.25 | $0.00 |
DisclosureSEC source: 0001415889-24-002608 · form4-02052024_050206.xml · derivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,500 Underlying: Common Stock · 304,500 shares Expires 2034-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 07:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-24-001062 · form4-01162024_070101.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 07:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 50,000 | $7.02 | $351,000.00 |
DisclosureSEC source: 0001415889-24-001062 · form4-01162024_070101.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2023 Filed Dec 12, 2023 17:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-23-016322 · form4-12122023_051203.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 12, 2023 Filed Dec 12, 2023 17:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 10,000 | $7.02 | $70,200.00 |
DisclosureSEC source: 0001415889-23-016322 · form4-12122023_051203.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2023 Filed Nov 22, 2023 19:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 9,145 | $13.89 | $127,024.05 |
DisclosureSEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 4 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,987 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.17. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 19:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 700 | $15.27 | $10,689.00 |
DisclosureSEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 3 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,132 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $15.27, and the range of prices was between $15.22 and $15.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 19:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 8,897 | $14.83 | $131,942.51 |
DisclosureSEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,832 F3 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $14.83, and the range of prices was between $14.18 and $15.17. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 19:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 36,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015455 · form4-11222023_071101.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,729 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 105,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. F2 · balance_after: Includes 9,034 shares acquired under the issuer's Employee Stock Purchase Plan on May 15, 2023 and 1,748 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006359 · form4-04072023_040409.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,197 F1 · price: The weighted average purchase price for the transaction reported was $3.4173, and the range of prices were between $3.375 and $3.42. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 5,000 shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 17:31 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006286 · doc4.xml · derivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 16:26 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009373 · form4-09062022_010928.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,197 F1 · price: The weighted average purchase price for the transaction reported was $3.59, and the range of prices were between $3.53 and $3.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 2,517 shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:04 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 247,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001056 · form4-02032022_040213.xml · derivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,000 Underlying: Common Stock · 247,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 18:47 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 107,604 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059517 · doc4.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,604 Underlying: Common Stock · 107,604 shares Expires 2030-11-17 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 15, 2020 Filed Nov 19, 2020 18:47 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 358,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059517 · doc4.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Ch. Operating & Financial Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,680 Read SEC document |
| May 09, 2017 Filed May 11, 2017 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001070081-17-000086 · wf-form4_149453761648390.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,625 Underlying: Common Stock · 10,000 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted on May 22, 2013, with 25% of the shares underlying the option vested on May 22, 2014, and an additional 2.083% of the original number of shares underlying the option vesting on a monthly basis thereafter, beginning on June 30, 2014. Read SEC document |
| May 09, 2017 Filed May 11, 2017 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $10.85 | $108,500.00 |
DisclosureSEC source: 0001070081-17-000086 · wf-form4_149453761648390.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 52,500 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001070081-17-000022 · wf-form4_148366154289045.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2027-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 00:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-17-000022 · wf-form4_148366154289045.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,850 F1 · shares: Restricted stock awarded to the Reporting Person vests in four equal annual installments over four years, commencing on January 3, 2018. Read SEC document |
| September 26, 2016 Filed Sep 26, 2016 20:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001179110-16-030032 · edgar.xml · derivative · entry 2 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,625 Underlying: Common Stock · 10,000 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award was granted on May 22, 2013, with 25% of the shares underlying the option vested on May 22, 2014, and an additional 2.083% of the original number of shares underlying the option vesting on a monthly basis thereafter, beginning on June 30, 2014. Read SEC document |
| September 26, 2016 Filed Sep 26, 2016 20:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $10.85 | $108,500.00 |
DisclosureSEC source: 0001179110-16-030032 · edgar.xml · nonDerivative · entry 1 Kovacs Shane William Charles · CIK 0001579397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.